Cargando…
OnabotulinumtoxinA in the treatment of patients with chronic migraine: clinical evidence and experience
Chronic migraine is a debilitating neurobiological disorder that affects approximately 1.4–2.2% of the population worldwide. Patients with chronic migraine have 15 or more headache days per month, with at least 8 days per month that meet the criteria for migraine. Injection of onabotulinumtoxinA, us...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703105/ https://www.ncbi.nlm.nih.gov/pubmed/29204191 http://dx.doi.org/10.1177/1756285617731521 |